These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32295428)

  • 1. Analysis of anticoagulation reversal survey (ARES).
    Rowe AS; Dietrich S; Hamilton LA
    Hosp Pract (1995); 2020 Aug; 48(3):123-127. PubMed ID: 32295428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding and antidotes in new oral anticoagulants.
    Majeed A; Schulman S
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
    Huisman MV; Fanikos J
    Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
    Hussain SS; Tyroch AH; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients.
    Allison TA; Lin PJ; Gass JA; Chong K; Prater SJ; Escobar MA; Hartman HD
    J Intensive Care Med; 2020 Sep; 35(9):903-908. PubMed ID: 30244638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
    Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
    J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
    Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS
    Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Four-factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors versus Warfarin in Life-threatening Bleeding.
    Rech MA; Masic D; Hammond DA
    West J Emerg Med; 2021 Feb; 22(2):163-169. PubMed ID: 33856296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
    Gibler WB; Racadio JM; Hirsch AL; Roat TW
    Crit Pathw Cardiol; 2019 Sep; 18(3):143-166. PubMed ID: 31348075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal)].
    Vicente V; Martín A; Lecumberri R; Coll-Vinent B; Suero C; González-Porras JR; Marco P; Mateo J; Roldán V; Soulard S; Crespo C; Camats M;
    Emergencias; 2017 Feb; 29(1):18-26. PubMed ID: 28825264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal agents for use with direct and indirect anticoagulants.
    Smythe MA; Trujillo T; Fanikos J
    Am J Health Syst Pharm; 2016 May; 73(10 Suppl 2):S27-48. PubMed ID: 27147456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing the anticoagulation effects of dabigatran.
    Dager WE; Banares L
    Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
    Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.